Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

Genetically modified Lactococcus lactis secreting interleukin 10 provides a therapeutic approach for inflammatory bowel disease. However, the release of such genetically modified organisms through clinical use raises safety concerns. In an effort to address this problem, we replaced the thymidylate synthase gene thyA of L. lactis with a synthetic human IL10 gene. This thyA− hIL10+ L. lactis strain produced human IL-10 (hIL-10), and when deprived of thymidine or thymine, its viability dropped by several orders of magnitude, essentially preventing its accumulation in the environment. The biological containment system and the bacterium's capacity to secrete hIL-10 were validated in vivo in pigs. Our approach is a promising one for transgene containment because, in the unlikely event that the engineered L. lactis strain acquired an intact thyA gene from a donor such as L. lactis subsp. cremoris, the transgene would be eliminated from the genome.

[1]  L. Hammarström,et al.  In situ delivery of passive immunity by lactobacilli producing single-chain antibodies , 2002, Nature Biotechnology.

[2]  M. Hecker,et al.  Escherichia coli K12 relA strains as safe hosts for expression of recombinant DNA , 2004, Applied Microbiology and Biotechnology.

[3]  Eduardo Diaz,et al.  Universal barrier to lateral spread of specific genes among microorganisms , 1994, Molecular microbiology.

[4]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[5]  Juan L. Ramos,et al.  Construction of an Efficient Biologically ContainedPseudomonas putida Strain and Its Survival in Outdoor Assays , 1998, Applied and Environmental Microbiology.

[6]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. , 2000, Gastroenterology.

[7]  G. Teti,et al.  Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria , 2000, Nature Biotechnology.

[8]  E. Remaut,et al.  Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by Recombinant Strains of Lactococcus lactis Coexpressing Antigen and Cytokine , 1998, Infection and Immunity.

[9]  S. Ehrlich,et al.  The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. , 2001, Genome research.

[10]  J. Wells,et al.  The isolation of lactococcal promoters and their use in investigating bacterial luciferase synthesis in Lactococcus lactis. , 1995, Gene.

[11]  M. Gasson,et al.  Construction of a food-grade host/vector system for Lactococcus lactis based on the lactose operon. , 1995, FEMS microbiology letters.

[12]  H. Barner,et al.  STUDIES ON UNBALANCED GROWTH IN ESCHERICHIA COLI. , 1954, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. O'Gara,et al.  Cloning and characterization of the thymidylate synthase gene from Lactococcus lactis subsp. lactis , 1990, Applied and environmental microbiology.

[14]  M. Kleerebezem,et al.  Use of the alr Gene as a Food-Grade Selection Marker in Lactic Acid Bacteria , 2002, Applied and Environmental Microbiology.

[15]  S. Ehrlich,et al.  High-efficiency gene inactivation and replacement system for gram-positive bacteria , 1993, Journal of bacteriology.

[16]  A. Eisenstark,et al.  Thymine metabolism and thymineless death in prokaryotes and eukaryotes. , 1998, Annual review of microbiology.

[17]  W. Stemmer,et al.  Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. , 1995, Gene.

[18]  W. D. de Vos,et al.  Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. , 1990, Gene.

[19]  F. Bringel,et al.  A host factor absent from Lactococcus lactis subspecies lactis MG1363 is required for conjugative transposition , 1991, Molecular microbiology.

[20]  T. Mosmann,et al.  Interleukin 10: a novel stimulatory factor for mast cells and their progenitors , 1991, The Journal of experimental medicine.

[21]  Vandekerckhove,et al.  Secretion of biologically active murine interleukin-10 by Lactococcus lactis. , 2000, Enzyme and microbial technology.

[22]  J. García,et al.  A gene containment strategy based on a restriction-modification system. , 2000, Environmental microbiology.

[23]  G. Venema,et al.  A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes , 1995, Journal of bacteriology.

[24]  J. Barbero,et al.  Production and secretion of human interleukin 6 into the periplasm of Escherichia coli: efficient processing of N-terminal variants of hIL6 by the E. coli signal peptidase. , 1993, Journal of biotechnology.

[25]  Jian‐guo Xu,et al.  Development of a Chromosome‐Plasmid Balanced Lethal System for Lactobacillus acidophilus with thyA Gene as Selective Marker , 2000, Microbiology and immunology.

[26]  K. I. Sørensen,et al.  A Food-Grade Cloning System for Industrial Strains of Lactococcus lactis , 2000, Applied and Environmental Microbiology.

[27]  S. Knudsen,et al.  Development and testing of improved suicide functions for biological containment of bacteria , 1995, Applied and environmental microbiology.

[28]  C. Elson,et al.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. , 1997, Gastroenterology.

[29]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[30]  W. Fiers,et al.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. , 2000, Science.

[31]  P. R. Jensen,et al.  Bacteriophage Resistance of a ΔthyA Mutant of Lactococcus lactis Blocked in DNA Replication , 2002, Applied and Environmental Microbiology.

[32]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[33]  H. Henderickx,et al.  Gastro-intestinal cannulation in pigs: a simple technique allowing multiple replacements. , 1977, Journal of animal science.

[34]  D. Scadden,et al.  Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. , 1995, Blood.

[35]  J. Ramos,et al.  Suicidal genetic elements and their use in biological containment of bacteria. , 1993, Annual review of microbiology.